P-0237 - Carboplatin Plus Fluorouracil (CF) as Salvage Treatment After Failure of Standard Chemotherapy in Patients with Metastatic Colorectal Cancer

Abstract

Background: There has been limited treatment option for metastatic colorectal cancer (CRC) patients that was previously treated with fluorouracil (FU), oxaliplatin, and irinotecan. Methods: We analyzed 63 patients with metastatic CRC who had been treated by carboplatin and fluorouracil (CF) between March 2008 and December 2011. All patients had failed standard therapy including FU, oxaliplatin, and irinotecan. Results: The median age of the 63 patients was 58 years (range: 21-80) and their median Eastern Cooperative Oncology Group performance status (ECOG PS) was 1 (0-1). Complete or partial response was not observed. The disease control rate was 31.7%. The median progression free survival (PFS) was 1.73 months (95% C.I. 1.54-1.92) and the median overall survival (OS) was 6.5 months (95% C.I. 5.09-7.91). In univariate and multivariate analysis, any clinico-pathologic features including sex, ECOG PS, grade, disease status, the location of primary tumor, the number of metastatic sites and the status of KRAS mutations did not have a major prognostic value regarding PFS or OS. Grade 3 or 4 non-hematologic toxicities included diarrhea in 1 patient. There were 14 patients with grade 3 or 4 hematologic toxicities, but no treatment related deaths. Conclusion: The CF showed moderate disease control rate and a tolerable toxicity profile as salvage therapy for metastatic CRC patients who were refractory to standard chemotherapy with no further treatment option.